The FDA on May 4, 2022, approved ENHERTU® for adult patients with unresectable or metastatic HER2-positive breast cancer, who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of completing therapy. ENHERTU® is a product of Daiichi Sankyo, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
